Antibe Therapeutics Inc. Antibe Therapeutics Inc.

Antibe Therapeutics Inc.

ATE

Classifica tra le azioni #31832
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Prezzo delle azioni
$0.21483059
Ultima sincronizzazione: 2024-05-07
Capitalizzazione di mercato
$11.13M
Variazione (1 giorno)
0.34%
Variazione (1 anno)
-0.36%
Paese
CA
Scambia Antibe Therapeutics Inc. (ATE)

Categoria

Healthcare
Storico del prezzo dell'azione per Antibe Therapeutics Inc. (ATE)
Prezzo di chiusura più alto: $0.22 il 2025-04-01

Prezzo di chiusura più basso: $4.78 il 2014-10-01
Storico del prezzo dell'azione di Antibe Therapeutics Inc. dal 2014 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2025 -0.02%
2024 -64.79%
2023 73.56%
2022 -33.35%
2021 -82.11%
2020 -6.13%
2019 60.42%
2018 70.25%
2017 -45.71%
2016 86.85%
2015 -71.73%
2014 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$100.56 -21.41%
US
$93.07 -2.95%
IE
$297.13 -23.49%
US
$44.47 -57.18%
US
$46.69 -18.50%
DE